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Abstract Fructose 2,6-bisphosphate is a potent endogenous
stimulator of glycolysis. A high aerobic glycolytic rate often
correlates with increased cell proliferation. To investigate this
relationship, we have produced clonal cell lines of Rat-1
fibroblasts that stably express transgenes coding for 6-phospho-
fructo-2-kinase, which catalyzes the synthesis of fructose 2,6-
bisphosphate, or for fructose 2,6-bisphosphatase, which catalyzes
its degradation. While serum deprivation in culture reduced the
growth rate of control cells, it caused apoptosis in cells
overproducing fructose 2,6-bisphosphate. Apoptosis was inhibited
by 5-amino-4-imidazolecarboxamide riboside, suggesting that
5P-AMP-activated protein kinase interferes with this phenomen-
on.
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1. Introduction
F-2,6-P2 is a ubiquitous stimulator of 6-phosphofructo-1-
kinase, a key regulatory enzyme in the glycolytic pathway. Its
synthesis and degradation are catalyzed respectively by PFK-2
and FBPase-2, two activities that are borne by distinct cata-
lytic sites of a single protein [1]. Many tumor and fast growing
cells exhibit a high rate of glycolysis even under aerobic con-
ditions [2,3]. F-2,6-P2 has been reported to play a role in this
phenomenon. First, the concentration of F-2,6-P2 is often
higher in established lines of cancer cells than in the corre-
sponding normal tissue [4]. Second, PFK-2 activity, F-2,6-P2
concentration and glycolysis increase in quiescent ¢broblasts
when they are stimulated by growth factors or phorbol esters,
or are transformed by the v-src or v-fps oncogenes [4^6].
Third, PFK-2/FBPase-2 mRNA is induced in normal ¢bro-
blasts by serum or growth factors, by the v-src oncogene
product and by the G1/S transition of the cell cycle [7^10].
These observations raised the question as to whether F-2,6-
P2 might contribute to the mitogenic potential of the cells. If
this is so, normal ¢broblasts that overproduce F-2,6-P2 might
keep proliferating when cultured in conditions of serum re-
striction. Indeed, serum or mitogen deprivation induces
growth arrest in a G1-like state often termed Go. The aim
of this work was to evaluate the e¡ect of F-2,6-P2 on the
control of cell proliferation by serum in Rat-1 ¢broblasts, a
non-transformed diploid cell line. This was performed on clo-
nal cell lines obtained from ¢broblasts stably transfected with
expression vectors for rat PFK-2/FBPase-2 in which either the
FBPase-2 or the PFK-2 activity had been destroyed by site-
directed mutagenesis.
2. Materials and methods
2.1. Plasmids
Plasmid pBS-KSII/PFK-2-L-H258A, kindly provided by L. Ber-
trand, was obtained by introducing the H258A mutation in pBS-
KSII/PFK-2L [11] by site-directed mutagenesis with the primer
5P-CACTCTCACCAGCGCGGCATAGG-3P. As this plasmid lacked
the original ATG start site, this site was recovered by ligating an
EcoRI fragment from pBS-KSII/PFK-2-L to EcoRI-digested pBS-
KSII/PFK-2-L-H258A. The S32A mutation was introduced by pol-
ymerase chain reaction [12] using the antisense 5P-CTGTGGTATG-
GAGGCGCCCCTTCGC-3P and sense 5P-TTCACTAATTCTCC-
CACGATGGTG-3P primers. An EcoRI fragment from a clone
containing this mutation was ligated to EcoRI-digested pBS-KSII/
PFK-2-L-H258A to generate pBS-KSII/PFK-2-L-S32A-H258A. An
EcoRV-XbaI fragment of this plasmid was cloned into EcoRI-XbaI-
digested pUHD-10.3 (kindly provided by H. Bujard) downstream
from a minimal CMV promoter controlled by seven copies of the
Tet operator, to obtain the PFK-2 plasmid. The original ATG start
site was introduced into pBS-KSII/PFK-2-L-K54M [13] by ligating a
BglII fragment of this plasmid to BglII-digested pBS-KSII/PFK-2-L.
An EcoRV-XbaI fragment was cloned into EcoRI-XbaI-digested
pUHD-10.3 to obtain the FBPase-2 plasmid. The pTet-On plasmid
(pUHD17-1neo) expressing the doxycycline-inducible reverse Tet-re-
sponsive transcriptional activator under the control of the strong
CMV immediate early promoter was purchased from Clontech. This
plasmid also contains a cassette conferring resistance to geneticin.
pBSpacvp, a plasmid conferring resistance to puromycin, was a gen-
erous gift of J.C. Renauld.
2.2. Cells
Rat-1 ¢broblasts were maintained as monolayers in DMEM sup-
plemented with 10% TET-FCS (Clontech), 50 IU/ml of penicillin and
50 Wg/ml of streptomycin. Stable Tet-On transfectants of Rat-1 ¢bro-
blasts were obtained by lipofection using DOTAP (Boehringer, Mann-
heim) according to the manufacturer’s instructions, with 7.5 Wg of
pTet-On plasmid for 1.5U106 cells per 10-cm culture dish in
DMEM containing 0.5% Tet-FCS. The DOTAP-DNA complex was
left on the cells for 18 h, at which time the cells were washed with PBS
and incubated in fresh medium. Six hours later the cells were trypsi-
nized and transferred to DMEM containing 10% Tet-FCS and G418
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(Gibco BRL) at 450 Wg/ml. The medium was replaced every 4 days
until a non-clonal population resistant to G418 was obtained. When
used as controls these cells were kept in a medium containing G418.
To obtain the K clones and the P clones, Tet-On cells were stably
transfected by lipofection using DOTAP as described above, with 7.5
Wg of PFK-2 (K clones) or FBPase-2 (P clones) plasmid plus 50 ng
of pBSpacvp plasmid for 1.5U106 cells. After selection with puromy-
cin (1 Wg/ml), clonal populations were obtained by dilution and
screened for Fru-2,6-P2 concentration in the absence or presence of
doxycycline (1 Wg/ml). All the data shown refer to cells treated with
doxycycline.
2.3. BrdU incorporation and apoptosis
Cells were plated at 104 cells/well and incubated for 48 h under the
conditions indicated. BrdU was added 4 h before the end of the
incubation and its incorporation into DNA was determined with
the BrdU labeling and detection kit of Boehringer by measuring ab-
sorbance at 450 nm. For evaluation of apoptosis, the Cell Death
Detection ELISAPLUS of Boehringer was used according to the man-
ufacturer’s instructions. Cells were plated at 104 cells/well and incu-
bated for 48 h as indicated. Mono- and oligonucleosomes were de-
tected in cell lysates with biotinylated anti-histone and peroxidase-
coupled anti-DNA antibodies, followed by measurement of absorb-
ance at 405 nm. When indicated, the extent of apoptosis was calcu-
lated as absorbance of test lysate divided by absorbance of lysate from
control cells cultured in 10% serum containing medium. For detecting
apoptosis by the TUNEL reaction, the cells were incubated on slides
for 48 h under the conditions indicated, ¢xed for 30 min in a freshly
prepared solution of paraformaldehyde in PBS (4%) and permeabi-
lized for 2 min in an ice-cold permeabilization solution (0.1% Triton
X-100, 0.1% sodium citrate). The DNA strand breaks were identi¢ed
by labeling free 3P-OH termini with £uorescein-modi¢ed dUTP in the
presence of terminal deoxynucleotidyltransferase and detection with
anti-£uorescein sheep antibody FAB fragments conjugated with alka-
line phosphatase. After substrate reaction (fast red, Boehringer)
stained cells were identi¢ed by light microscopy. For the detection
of apoptosis by DNA ladders, cells were cultured for 48 h under
the conditions indicated, trypsinized, centrifuged and resuspended in
200 Wl of PBS (4‡C) for processing according to the apoptotic DNA
ladder kit of Boehringer with 2U106 cells per DNA extraction. After
puri¢cation of DNA, RNAse was added at 80 Wg/ml followed by a
30 min incubation at room temperature. The DNA samples were
electrophoresed in 1.2% agarose gels and DNA fragments were visual-
ized with ethidium bromide.
2.4. Other methods
To determine PFK-2 activity, frozen ¢broblasts were homogenized
in 50 mM KCl, 5 mM MgCl2, 2 mM EDTA, 5 mM potassium phos-
phate, 15 mM L-mercaptoethanol, 20 mM HEPES, 0.1 mM phenyl-
methylsulfonyl £uoride, pH 7.5. After centrifugation (20 800Ug for
10 min) the supernate was made 6% (v/v) in PEG-6000, left for 30 min
at 0‡C and centrifuged as above. The concentration of PEG in the
supernate was brought to 20% (30 min at 0‡C). After centrifugation as
above, the pellet was resuspended in homogenization bu¡er to reach a
protein concentration of about 1 mg/ml. Samples (10^20 Wl) were
incubated at 30‡C in 50 mM Tris-Cl, 100 mM KCl, 5 mM potassium
phosphate, 20 mM KF, 5 mM fructose 6-phosphate, 15 mM glucose
6-phosphate, 1 mM dithiothreitol, pH 8.5. The reaction was started
by adding 5 mM MgATP and stopped after 0^12 min by adding 1 vol
of 100 mM NaOH followed by incubation at 80‡C for 10 min. F-2,6-
P2 was measured as described [14]. AMPK activity was measured by
incubating 20 Wl of a 6% PEG-treated cell extract with 0.2 mM SAMS
peptide in the presence of 0.2 mM AMP [15]. PP-2A was puri¢ed
from bovine heart as described [16] and assayed with paranitrophenyl
phosphate. Lactate was measured by mixing 1 ml of culture medium
with 1 ml of 10% HClO4. After 10 min at 0‡C and centrifugation at
2000Ug for 10 min, the supernate was neutralized with 3 M KOH-
KHCO3 and lactate concentration was determined as described [17].
Protein concentration was determined by the Bio-Rad protein assay.
ATP and AMP were determined as described [18].
3. Results and discussion
3.1. Clonal selection of cells expressing PFK-2/FBPase-2
transgenes
Cells containing di¡erent amounts of F-2,6-P2 were ob-
tained by stably transfecting them with a PFK-2/FBPase-2
expression vector together with a plasmid conferring resist-
ance to puromycin. The PFK-2/FBPase-2 transgene chosen
codes for the L isozyme, which is regulated by PKA. Phos-
phorylation inactivates PFK-2 and activates FBPase-2. The
recipient cells were Tet-On transfectants, namely Rat-1 ¢bro-
blasts that we had stably transfected with an expression vector
for a doxycycline-inducible chimeric protein in which the Es-
cherichia coli reverse Tet repressor has been fused to the VP16
activation domain [19,20]. Puromycin-resistant clones called
‘K’ were obtained after transfecting Tet-On cells with a vector
expressing a double mutant of PFK-2/FBPase-2 in which the
FBPase-2 activity has been abolished by a H258A mutation
[21] and the inactivation of PFK-2 by PKA has been abol-
ished by a S32A mutation [22]. Such clones were expected to
contain a high concentration of F-2,6-P2. Clones called ‘P’
were likewise obtained after transfecting Tet-On cells with a
vector expressing a K54M mutant characterized by loss of
PFK-2 activity, but persistence of FBPase-2 activity and of
activability by PKA [13]. Such clones were expected to con-
tain a low concentration of F-2,6-P2. The transfected PFK-2/
FBPase-2 cDNA were driven by a promoter containing a
rTet-responsive element in view of inducing the transgenes
by doxycycline.
We isolated 63 K clones and 35 P clones. Each clonal cell
line was tested for F-2,6-P2 concentration after culture in the
presence or absence of doxycycline. For all the experiments,
we used as a control a non-clonal population of the stable
Tet-On transfectants. We selected eight K clones that had a
higher F-2,6-P2 content, and three P clones that had a lower
F-2,6-P2 content, than these control cells. Because of the leak-
iness [23] of the Tet-On system in our ¢broblast cell lines,
inducibility by doxycycline was never more than two to
three-fold. Still, in the presence of doxycycline, the concentra-
tion of F-2,6-P2 in some K clones reached up to 2000^3000
pmol/mg of protein, which was 40^60 times higher than in
control cells treated with doxycycline. The PFK-2 activity of
the K clones ranged from 160^570 WU/mg of protein as com-
pared to 85 for control cells and to 40^60 for the P clones.
Levels of F-2,6-P2 higher than 1000 pmol/mg of protein were
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Table 1
AMPK activity in ¢broblasts
AICAR 10% serum 0.5% serum
Control PP-2A Control PP-2A
3 1.21 þ 0.15 0.06 þ 0.01 0.61 þ 0.04 0.04 þ 0.01
+ 1.08 þ 0.11 0.08 þ 0.01 1.25 þ 0.01 n.d.
Tet-On cells were cultured for 48 h in medium containing 10% or 0.5% serum without or with addition of 1 mM AICAR 1 h before harvesting.
AMPK activity (nmol/min/mg of protein) was measured in cell extracts incubated for 30 min at 30‡C without (control) or with 11 U/ml PP2-A.
Data are means þ S.E.M. for three independent experiments. n.d., not detectable.
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not maintained with cell passages, in contrast to the stability
of F-2,6-P2 concentration over time in the P clones. This al-
ready argued against high F-2,6-P2 providing a selective ad-
vantage for proliferation.
3.2. E¡ect of serum starvation on cell proliferation in
PFK-2/FBPase-2 transfectants
We ¢rst compared the growth curves of a representative K
clone (K16) and P clone (P18), and of control cells. In the
presence of 10% serum the growth rates were similar for the
P clone and control cells and were slightly reduced for the
K clone (Fig. 1A). When serum concentration was reduced
to 0.5%, the growth rate of control cells was reduced, as ex-
pected. This was also the case for the P clone, while the
growth of the K clone did stop after 24 h. In fact, the number
of K cells decreased after 48 h of serum starvation which was
suggestive of cell death (Fig. 1B). These results ruled out the
hypothesis that F-2,6-P2 stimulates proliferation or can pre-
vent the decrease in DNA synthesis induced by serum starva-
tion. To con¢rm this, BrdU incorporation was measured
under the same conditions. The extent of DNA synthesis in
10% serum for the K clone was half that of the P clone or of
control cells (inset of Fig. 1A). Moreover, serum starvation
decreased DNA synthesis almost twice as much in the K clone
as in the P clone or control cells (inset of Fig. 1B). In view of
these results, we veri¢ed that serum starvation per se did not
in£uence transgene expression. It did not (Fig. 1C,D), as F-
2,6-P2 concentration remained high in the K clone and low in
the P clone under these conditions. The decrease in cell num-
ber observed for K clones upon serum starvation raised the
possibility that this was due to apoptosis. Indeed, while nor-
mal ¢broblasts reduce their growth in this situation, trans-
formed ¢broblasts have been reported to undergo, instead,
programmed cell death [24,25].
3.3. E¡ect of serum starvation on apoptosis in
PFK-2/FBPase-2 transfectants
As a measure of apoptosis, we detected free nucleosomes in
cell lysates from clone K16, clone P18 and control cells. Even
under standard culture conditions, i.e. with 10% serum, apop-
tosis was 4^5 times higher for clone K16 than for clone P18 or
for control cells (Fig. 2A). This di¡erence was dramatically
ampli¢ed (up to 23-fold) in 0.5% serum. This phenomenon
held true for the eight K clones tested (Fig. 2A), showing
that it was not the mere consequence of a chance genomic
event caused by the transgene in clone K16. Moreover, the
extent of apoptosis in serum starved cells was correlated to F-
2,6-P2 concentration (Fig. 2B). This was con¢rmed by meas-
uring apoptosis by two other methods, namely electrophoretic
separation of DNA fragments and TUNEL (not shown).
Consistent with these ¢ndings, microscopic examination
showed that 48 h after serum starvation the cells from clones
containing the highest F-2,6-P2 concentration were round and
refractile and lost adhesiveness and they exhibited cytoplasmic
shrinkage and chromatin condensation. The same morpholog-
ical changes were seen after three days of con£uence in 10%
serum for the K clones, but not for the P clones or for control
cells. Another characteristic of the clonal cell lines containing
very high F-2,6-P2 concentrations is that they did not survive
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Table 2
Anti-apoptotic e¡ect of AICAR
AICAR Apoptosis BrdU incorporation F-2,6-P2
(mO.D) (mO.D) (pmol/mg protein)
n = 4 n = 4 n = 3
3 987 þ 6.2 684 þ 15 273 þ 32
+ 297 þ 67 633 þ 27 241 þ 21
Cell from clone K16 were incubated for 48 h in 0.5% serum in the
absence or presence of 1 mM AICAR and the parameters were meas-
ured as described in Section 2. Data are means þ S.E.M. for the num-
ber (n) of experiments in each of which measurements were taken in
quadruplicate.
Fig. 1. E¡ect of serum starvation on the growth and glycolysis of ¢-
broblasts containing di¡erent concentrations of F-2,6-P2. The cul-
ture medium containing 10% serum was replaced at time zero by
fresh medium containing either 10% serum (A, C, E) or 0.5% serum
(B, D, F). Cells were seeded at about 105 cells/6-cm dish. At the
times indicated, samples were taken for measuring the number of
cells (results are expressed as ratio to number of cells at time zero)
and F-2,6-P2 concentration. BrdU incorporation (insets) was meas-
ured after 48 h of culture and the results are expressed as absorb-
ance units (mO.D). The data are means þ S.E.M. for three experi-
ments with control (b), P18 (F) or K16 (R) cells (E, F). The data
refer to lactate produced over the 48 h incubation and to F-2,6-F2
concentration determined at the end of the incubation period in the
experiments described in A^D. The three values for clone K16 cor-
respond to data obtained with cells that had been in culture for
26 (R), 58 (v) or 73 (8) days (see text).
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when plated at very low density in medium containing 10%
serum. We ruled out a toxic e¡ect of high concentrations of
F-2,6-P2, e.g. an inhibition of glycolytic enzymes, as the direct
correlation observed between lactate production and F-2,6-P2
concentration in 10% serum was maintained in 0.5% serum
(Fig. 1E,F). In fact, the glycolytic rate was higher under the
latter condition, consistent with the absence in the transgenes
of the serum response element contained in the promoter of
the PFK-2/FBPase-2 gene [8]. All these experiments showed
that overproduction of F-2,6-P2, far from maintaining cell
proliferation upon growth factor withdrawal, does increase
susceptibility to apoptosis.
3.4. Involvement of AMPK
Work by others [26] has provided evidence that AMPK can
inhibit the apoptotic cascade triggered by glucocorticoid treat-
ment of thymic lymphocytes. Moreover, in mouse ¢broblasts
AMPK phosphorylates Raf-1 [27], a protein kinase which is
thought to inhibit apoptosis by interacting with Bcl-2 and
BAG-1 [28]. AMPK serves as a ‘metabolic sensor’ or ‘fuel
gauge’ that is activated by an increased AMP:ATP ratio
[29,30]. This enzyme switches on ATP-producing pathways,
switches o¡ ATP-consuming pathways and protects the cell
against nutritional stress. On the other hand, stimulation of
AMPK activity interferes with the induction of gene transcrip-
tion by glucose metabolites [31,32].
These observations led us to test whether decreased AMPK
activity could be involved in the apoptotic e¡ect of F-2,6-P2.
We ¢rst veri¢ed that Rat-1 ¢broblasts contain AMPK activ-
ity. This was the case (Table 1). As expected, AMPK activity
was decreased after incubation of the cell extracts with PP-2A,
a phosphoprotein phosphatase that inactivates AMPK
[29,30]. Consistent with our hypothesis, AMPK activity in
control cells decreased by about 50% upon serum starvation
(Table 1), a situation shown above (Fig. 2) to be accompanied
by increased susceptibility to apoptosis. This decrease in
AMPK activity was not due to a decreased AMP:ATP ratio,
as this ratio was 0.04 in cells cultured in 10% serum and 0.06
in 0.5% serum. Moreover, AMPK activity was assayed with a
saturating concentration (0.2 mM) of AMP and after removal
of allosteric inhibitors and activators. Thus, serum starvation
could either decrease the amount of AMPK protein or the
activity of AMPK kinase, which activates AMPK by phos-
phorylation [29,30].
To validate our hypothesis, we tested whether an agent that
increases AMPK activity can protect the cells against the
apoptotic phenomenon described here. AMPK kinase is, like
AMPK, stimulated by AMP. We therefore incubated the cells
with AICAR (Z-riboside). AICAR is converted into ZMP, an
AMP analog known to activate AMPK [30]. Treatment of
serum starved cells with AICAR restored AMPK activity to
the level seen with 10% serum (Table 1). AMPK activity in
extracts from AICAR-treated cells was decreased by PP-2A,
as expected (Table 1). Preliminary data showed that in keep-
ing with our hypothesis, AMPK activity was smaller in serum
starved K clones than in serum starved control cells. We
therefore determined whether AICAR treatment could protect
clone K16 against apoptosis induced by serum starvation.
This was the case (Table 2). If AICAR was added to the
cultured K clone when serum concentration was reduced,
apoptosis measured 48 h later was 3.3-fold lower than in
the absence of AICAR. This was con¢rmed by TUNEL anal-
ysis (not shown). There was no e¡ect of AICAR treatment on
F-2,6-P2 concentration or on DNA synthesis (Table 2).
In conclusion, the data presented here discount the hypoth-
esis that F-2,6-P2 protects the cells against growth factor
withdrawal. Instead, they show that a high F-2,6-P2 concen-
tration correlates with increased susceptibility to apoptosis
and suggest that AMPK can interfere with this phenomenon.
These results should shed light on the ill-explained ¢nding
that hyperglycaemia can induce apoptosis in several systems
[33,34].
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